guest ::
| Home > Authorities > Grants > Record #1048920 > print |
| Home > Authorities > Grants > Record #1048920 > print |
| 001 | 1048920 | ||
| 005 | 20251208091715.0 | ||
| 024 | 7 | _ | |2 CORDIS |a G:(EU-Grant) 101124542 |d 101124542 |
| 024 | 7 | _ | |2 CORDIS |a G:(EU-Call)ERC-2023-COG |d ERC-2023-COG |
| 024 | 7 | _ | |2 originalID |a corda__h2020::101124542 |
| 035 | _ | _ | |a G:(EU-Grant)101124542 |
| 150 | _ | _ | |a
Deciphering fibrosis reversal mechanisms in chronic blood cancer for identification of novel predictive and therapeutic strategies
|y 2024-04-01 - 2029-03-31 |
| 372 | _ | _ | |a ERC-2023-COG |s 2024-04-01 |t 2029-03-31 |
| 510 | 1 | _ | |0 I:(DE-588b)5098525-5 |2 CORDIS |a European Union |
| 680 | _ | _ | |a
Is it possible to reverse fibrosis? When there is injury or damage to an organ, the normal healing process involves the formation of new tissue. When this process becomes dysregulated, it leads to the formation of excessive fibrous connective tissue causing fibrosis. Funded by the European Research Council, the Rewind-MF project focuses on primary myelofibrosis, a blood malignancy associated with the activation of fibrosis-driving cells in the bone marrow. The study explores the reversibility of fibrosis, particularly in cases where allogeneic stem cell transplantation is not a viable option. By delving into the mechanisms of reversing fibrosis, researchers expect to identify therapeutic targets and understand how blood cancer is sustained in the bone marrow.
|
| 909 | C | O | |o oai:publications.rwth-aachen.de:1022762 |p authority:GRANT |p authority |
| 980 | _ | _ | |a G |
| 980 | _ | _ | |a CORDIS |
| 980 | _ | _ | |a AUTHORITY |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|